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1.1 Chemicals, reagents and Drug Administration.  
(S)-N-tert-Butyl-3-(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamide 
dihydrochloride ((S)-WAY 100135 dihydrochloride), 2-[(1,2-Dihydro-2-oxo-3H-indol 3-yl 
idene)methyl]-4-methyl-1H-pyrrole-3-propanoic acid (SU 5402), N-[2-[[4 
(Diethylamino)butyl]amino]-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N' 
(1,1dimethylethyl)urea (PD173074) and (±)-7-Hydroxy 2-dipropylaminotetralin 
hydrobromide (8-OH-DPAT hydrobromide) were purchased from Tocris Cookson Inc. 
FGF-2 was purchased from Cell Signalling Technology (Stockholm, Sweden). Dulbecco's 
modified Eagle's medium, penicillin/streptomycin, and fetal bovine serum was purchased 
from Invitrogen. Restriction enzymes were from New England Biolabs (Stockholm, 
Sweden), and coelenterazine 400 was obtained from MRW (Stockholm, Sweden). The 
injected amounts (i.c.v.) were 8-OH-DPAT (60g) and FGF-2, (50ng) unless otherwise 
indicated. Phospho-FGF Receptor 1 (Tyr653/654) (55H2) mouse monoclonal antibody was 
purchased from Cell Signalling Technology (Stockholm, Sweden). Rabbit polyclonal 
antiserum against 5-HT1A receptor (ab44635), mouse monoclonal [M2F12] FGFR1 
(ab829) antibodies were obtained from Abcam (Stockholm, Sweden). Rabbit monoclonal 
 2 
anti-5-HT1A (vtg544) antibody was obtained from VTG Biosciences (Stockholm, Sweden). 
Monoclonal mouse anti-phospho-ERK1/2 and rabbit monoclonal anti-5-HT antibodies 
were from Sigma-Aldrich (Stockholm, Sweden). Mouse anti-NeuN monoclonal antibody 
was purchased from Millipore (Stockholm, Sweden). Secondary infrared probe-labelled 
rabbit-anti-mouse antibodies were from LI-COR Biosciences (Stockholm, Sweden). Alexa 
Fluor 488-conjugated goat anti-mouse IgG and the Alexa Fluor 546-conjugated goat anti-
rabbit IgG were from Invitrogene (Stockholm, Sweden). 
1.2 Plasmid constructs. The cDNA encoding the human 5-HT1A and FGFR1 without its 
stop codon was subcloned in pGFP2-N1 (Perkin-Elmer, Madrid, Spain) and pEYFP-N1 
(Clontech, Heidelberg, Germany) using standard molecular biology and PCR techniques. 
1.3 Cell culture, transfection, RNA interference.   
HEK293T or RN33B cells (a CNS-derived neuronal precursor cell line) (American Type 
Culture Collection, Manassas, VA, USA) were grown in Dulbecco's modified Eagle's 
medium/F12 supplemented with 2 mM L-glutamine, 100 units/ml penicillin/streptomycin, 
and 10% (v/v) foetal bovine serum (FBS) at 37 °C and in an atmosphere of 5% CO2. For 
transfection, cells were plated in 6-well dishes at a concentration of 1×106 cells/well or in 
75cm2 flasks and cultured overnight before transfection. Cells were transiently transfected 
(cDNA molar ratio 1:1) using linear PolyEthylenImine reagent (PEI) (Polysciences Inc., 
Warrenton PA, USA). siRNAs against rat FGFR1 and 5-HT1A were from 
Dharmacon/Thermo Scientific (Stockholm, Sweden). Non-silencing siRNA Alexa Fluor 
488 was from Qiagen (Cat No 1022563) and used as a negative control. Cells were plated 
the day before transfection in 12-well culture dishes coated with poly-D-lysine (BD 
Biocoat, USA) and then transfected with the corresponding SMARTpool siRNA kit 
(Dharmacon). 
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1.4 Transmembrane peptide treatment. A series of peptides, representing each of the 
predicted TM segments for the human 5-HT1A (UniProt identifier number: P08908) were 
synthesized by VTG Biosciences (Stockholm, Sweden) by using 9-
fluorenylmethoxycarbonyl chemistry and purified by means of high-performance liquid 
chromatography (HPLC) analysis (reverse phase C4 column) to ≥ 98% purity. At the C-
terminal juxtamembrane sequence of each TM peptide was introduced the tribasic sequence 
(RKR) as found in many membrane proteins in order to reduce possible artefact formation 
through disulfide bridges and to ensure incorporation into the plasma membrane of cells  as 
has been demonstrated previously [12,16]. Immediately before use, the peptides were 
solubilised in dimethyl sulfoxide (DMSO) and diluted in the corresponding cell culture 
medium to yield a final concentration of 1% DMSO. We verified that, for each tested 
concentration of DMSO alone, no effect on cell viability was observed. Cells were 
incubated with the above mentioned peptides at 37°C for two hours prior to performing 
FRET analysis or signalling assays. Incorporation of the peptide into cellular membranes 
under these conditions was checked with a rhodamine-labeled TM-I peptide.  
1.5 5-HT Immunocytochemistry. RN33B cells were treated under different pharmacological 
conditions as indicated and grown for an additional 48-56 hour (in the case of TM peptide 
incubation, neurons where incubated 2 hours before pharmacological treatment). RN33B 
cells were stained with rabbit anti-5-HT monoclonal antibody (5 µg/ml; Sigma-Aldrich) 
and mouse anti-NeuN monoclonal antibody (5 µg/ml; Millipore). The secondary antibodies 
used were as follows: Alexa Fluor 488-conjugated goat anti-mouse IgG (1:2000; Invitrogen, 
Stockholm, Sweden), Alexa Fluor 546-conjugated goat anti-rabbit IgG (1:2000; Invitrogen, 
Stockholm, Sweden). Each image was acquired with a Leica SP2 confocal microscope 
(40×) and consisted of one image as a single z-scan image. Acquisition of microscopy 
images and 5-HT immunoreactivity semi-quantifications were performed by investigators 
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blind to the experimental condition. 5-HT immunoreactivity semi-quantification is 
expressed as intensity of 5-HT immunoreactivity per field area or per NeuN positive cell). 
Typically, images of 200-300 cells per condition were captured for each experiment and 
four independent experiments were performed. The application settings were adjusted at the 
beginning of analysis and kept the same for all images in the experiment.  
1.6 Animals and drugs. Male Sprague–Dawley rats, 8 weeks old, weighing 310–350 g 
obtained from Charles River Laboratories were used for all experiments. The animals were 
housed under a 12-h light/dark cycle under constant environmental conditions, with 
ambient temperature of 21 ± 2 °C, relative humidity of 40-50% and with food and water 
available ad libitum. The number of rats in each treated group was three and the total 
number of rats used in this study was 36. All efforts were made to minimize the number of 
animals used and their suffering. All experimental procedures were performed in 
accordance with the European Communities Council Directive (86/609/EEC) and 
(2010/63/EU). 
1.7  Surgical preparation. Rats were anaesthetized with sodium pentobarbital (40 mg/kg, 
i.p., Nembutal injection, Dainippon Pharmaceutical) and placed in a stereotaxic frame. 
Body temperature was maintained at 37°C and cannula for i.c.v. injection of samples was 
implanted into the right lateral ventricle according to coordinates obtained from Paxinos 
and Watson (anterior posterior (AP) co-ordinates referred to bregma, lateral (L) co-
ordinates to the midsagittal suture line, and ventral coordinates (V) to the surface of the 
skull. AP, -1.4 mm; L, ±2.2 mm and V, -4.3 mm (injection site). Permanent guide cannula 
was maintained in place by dental cement anchored by stainless screws fixed to the skull 
and fitted with an obturator. Five days after surgery, the obturators were removed and a 28-
gauge injector cannula was inserted extending 1.5 mm below the tip of the guides. The 
microinjection cannula was connected via PE-20 tubing to a Hamilton syringe mounted on 
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a syringe pump (Harvard Apparatus). Rats were microinjected with recombinant human 
FGF-2 (50ng), 8-OH-DPAT (0.2 micromoles), combined treatment with TM-II synthetic 
peptide (0.4micromoles), combined treatment with TM-V synthetic peptide 
(0.4micromoles), and treatment with artificial cerebrospinal fluid (aCSF) for a control 
group. Fresh solutions were prepared immediately before the injections by dissolving the 
peptides/agonists aCSF (composition of the aCSF solution was: 120 mM NaCl, 20 mM 
NaH2CO3, 2 mM KCl, 0.5 mM KH2PO4, 1.2 mM CaCl2, 1.8 mM MgCl2, 0.5 mM Na2SO4 
and 6.8 mM d-glucose). Total volumes were infused (FGF-2: 2µl; 8-OH-DPAT: 3µl; TM 
synthetic peptides: 3µl) in freely moving animals at 2.0 µl/min and injection cannula were 
left in place for another minute to prevent backflow of the solution. The animals were 
killed 6h, 12h or 24 h after the infusions. 
1.8  Western blot analysis in animal tissue preparation. Raphe midline area of the midbrain 
tissue was homogenized in cold RIPA buffer (50mM TrisHCl pH7.4, 150mM NaCl, 
1%triton, 0.1%SDS and H2O), protease inhibitor cocktail (Sigma-Aldrich, cat. num P8340), 
and phosphatase inhibitor cocktail 2 (Sigma-Aldrich, cat. num P5726), left on ice for 30 
min. and then centrifuged at 10,000g for 30 min at 4°C. The supernatant was collected and 
stored at −20°C and an aliquot taken for protein determination by the BCA method. The 
supernatant samples (50 µg per lane) and molecular weight biotinylated markers 
(RPN2107, GE Healthcare Europe GmbH, Milan Italy), were run on 10% polyacrylamide 
gel and electrophoretically transferred onto nitrocellulose membrane (RPN303E, Hybond-
C-extra, GE Healthcare Europe GmbH, Milan Italy). The membranes were incubated for 1h 
in blocking buffer : 1x TBS, 0.1%Tween-20, 5% w/v nonfat dry milk. Following three 
washings for 5 min. with TBS/T, the membranes were incubated with gentle shaking 
overnight at -4°C with a specific antibody in primary antibody dilution buffer: 1x TBS, 
0.1%Tween-20, 5% BSA. For detection of pERK1/2 and pFGFR the following antibodies 
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were used: rabbit anti-Phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204) antibody (9101 
Cell Signaling) diluted 1:1000 and mouse anti-p-FGFR (Tyr653/654) antibody (Cell 
Signaling 55H2) diluted 1:1000. Following three washing for 5 min with TBS/T the 
membranes were incubated for 1 h at room temperature with anti-rabbit IgG horseradish 
peroxidase-conjugated diluted 1:8000 (Sc 2054, Santa Cruz Biotechnology, Inc. 
Heidelberg, Germany) and goat anti-mouse IgG horseradish peroxidase-conjugated diluted 
1:7000 (sc-2005 Santa Cruz Biotechnology). Immuno-complexes were visualized with 
chemiluminescence reagent (RPN2108, GE Healthcare Europe GmbH, Milan Italy) 
according to the manufacturer's instructions. The Hyperfilm (ECL-films 28906837, GE 
Healthcare Europe GmbH, Milan Italy) were developed using Kodak developer and fixer 
(catalog No. 1900984 and 1902485, Kodak GBX, Eastman Kodak)., and the densitometric 
evaluation of bands was performed by measuring the optical density (O.D.) using the Image 
J software (Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, 
USA, http://rsb.info.nih.gov/ij/, 1997-20011) or Image Gauge V4.0 from Fujifilm.  
 
FIGURES 
Supplementary Figure 1. FGFR1-5-HT1A heteroreceptor complexes role in 5-HT 
synthesis and storage in RN33B cells. (A) Effects of TM peptide incubation on 5-HT 
immunoreactivity in RN33B cell cultures after coactivation with 8-OH-DPAT and FGF-2 
which produces a marked increase of 5-HT immunoreactivity. Red colour was used as a 
marker for 5-HT storage and NeuN immunoreactivity (green colour) as a marker for 
neuronal nuclei. RN33B brain-derived immortalized cells were treated for 48 hours without 
(Control) or with FGF-2 (50ng/ml) and 8-OH-DPAT (100nM). Treatment with TM 
peptides (0.4µM)  involved TM-II and TM-V as indicated. 5-HT immunoreactivity was 
visualized by immunofluorescent labelling with 5-HT. 5-HT immunoreactivity was 
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determined in sample fields of a constant size divided by the number of NeuN nuclei. 
Representative images of 5-HT/NeuN-stained RN33B cells under different conditions are 
presented. Scale bar represents 20 µm. The quantification is seen in (B) where the data are 
presented as mean ± s.e.m, n=4. The combined group is significantly different from 8-OH-
DPAT and FGF-2 alone groups (+++P<0.001); the mean 5-HT immunoreactivity value of 
the group treated with TM peptide V is highly significantly reduced versus the combined 
treated group (***P<0.001). Also the FGF-2 treated alone group is significantly different 
from the 8-OH-DPAT alone group (## P<0.01). The following concentrations were used: 8-
OH-DPAT, 100nM; FGF-2, 50ng/ml and each TM peptide, 0.4µM. Statistical analysis was 
performed by one-way analysis of variance (ANOVA) followed by Tukey's Multiple 
Comparison post-test. The P value 0.05 and lower was considered significant.  
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